ライフサイエンスコーパス: pancytopenia

1 ive depletion of all hematopoietic lineages (pancytopenia).

2 d by hypoplastic bone marrow and progressive pancytopenia.

3 e implicated in the development of anemia or pancytopenia.

4 tem cells prior to the development of severe pancytopenia.

5 e alterations of hematopoiesis, resulting in pancytopenia.

6 resented to the Cancer Clinic with fever and pancytopenia.

7 ne patient with grade 4 acute GVHD developed pancytopenia.

8 , the patient developed new skin lesions and pancytopenia.

9 n with Babesia may be associated with marked pancytopenia.

10 -1995) that presented data on MTX-associated pancytopenia.

11 rtality due to graft-versus-host disease and pancytopenia.

12 ypocellular bone marrow and peripheral blood pancytopenia.

13 up: one because of sepsis and one because of pancytopenia.

14 definitive therapies in patients with severe pancytopenia.

15 multiple tick bites presented with fever and pancytopenia.

16 occlusive disease, capillary hemorrhage, and pancytopenia.

17 erized by hypocellular marrow and peripheral pancytopenia.

18 ed severe macrocytic normochromic anemia and pancytopenia.

19 cell (HSC) division, rapid HSC depletion and pancytopenia.

20 cell transplant and relapse with refractory pancytopenia.

21 ell expansion and rescued animals from fatal pancytopenia.

22 irth, likely due to pulmonary hypoplasia and pancytopenia.

23 F-2alpha, encoded by the EPAS1 gene, exhibit pancytopenia.

24 veral stages that is characterized by severe pancytopenia.

25 hat the loss of EPAS1/HIF-2alpha resulted in pancytopenia.

26 One patient developed reversible pancytopenia.

27 ted with reduced doses because of persistent pancytopenia.

28 to produce immunosuppression had continuous pancytopenia.

29 Grade 3 events occurred in 3 patients-1 with pancytopenia, 1 with leukocytopenia, and 1 with pain fla

30 ic GVHD (60.7%; 95% CI, 50.3% to 71.1%), and pancytopenia (18.6%; 95% CI, 12.2% to 25.0%).

31 resented with fever, hepatosplenomegaly, and pancytopenia; 5 were previously healthy, but had a clini

32 Clinical features were skin rash (92%), pancytopenia (78%), and diarrhea (65%).

33 The patient suffered from pancytopenia, allergy, asthma, hearing impairment, and m

34 que manifestation of bone marrow failure and pancytopenia among diseases caused by DNA damage respons

35 ilance data to investigate the occurrence of pancytopenia among patients with cancer treated with pol

36 one marrow failure disorder characterized by pancytopenia and a hypocellular marrow.

37 two (2%) patients each in the benralizumab (pancytopenia and a suicide attempt, both considered unre

38 (one with acute myeloid leukaemia, one with pancytopenia and acute cardiac failure) and four patient

39 truction of hematopoietic stem cells causing pancytopenia and an empty bone marrow, which can be succ

40 nge of hematopoietic abnormalities including pancytopenia and BM hypoplasia similar to individuals wi

41 be difficult to distinguish in patients with pancytopenia and bone marrow hypocellularity.

42 autosomal recessive disorder associated with pancytopenia and cancer susceptibility.

43 is a fatal genetic disorder associated with pancytopenia and cancer.

44 We investigated the mechanisms of profound pancytopenia and did not observe activation of CAR-37 T

45 Deletion of Dot1l led to pancytopenia and failure of hematopoietic homeostasis, a

46 nd symptoms of GSD type Ib are hypoglycemia, pancytopenia and hepatosplenomegaly.

47 conditions of anemia, thrombocytopenia, and pancytopenia and how the biochemical and biophysical pro

48 ressive decline in mentation associated with pancytopenia and hyperbilirubinemia.

49 mopoietic stem-cell disorder that results in pancytopenia and hypocellular bone marrow.

50 in addressing the immediate consequences of pancytopenia and in the long term because of the disease

51 mmon hematologic malignancy characterized by pancytopenia and marked susceptibility to infection.

52 xpression interferes with the development of pancytopenia and marrow hypoplasia, validating a major r

53 marrow disorder characterized by peripheral pancytopenia and marrow hypoplasia.

54 Because of sustained pancytopenia and negligible gene marking, diagnostic bon

55 UCB, GVHD in 4 patients, and immune-mediated pancytopenia and nephrotic syndrome in the recipient of

56 She was diagnosed with pancytopenia and passed away after 5.5 months.

57 in the chemotherapy group, one [<1%] due to pancytopenia and sepsis and one [<1%] haemothorax).

58 specifically associated with neonatal-onset pancytopenia and severe autoinflammation/hemophagocytic

59 conferred in vivo resistance to BCNU-induced pancytopenia and significantly reduced BCNU-induced mort

60 tion of Lkb1 in adult mice results in severe pancytopenia and subsequent lethality.

61 estigated the mechanisms by which AML causes pancytopenia and suppresses patients' immune response.

62 ry disease in view of the longer duration of pancytopenia and susceptibility to life-threatening infe

63 Pancytopenia and systemic infections in particular were

64 nd two (1%) in the platinum-etoposide group (pancytopenia and thrombocytopenia [n=1 each]).

65 topenias (thrombocytopenia, neutropenia, and pancytopenia) and HMs (acute myeloid leukemia, myelodysp

66 tis, 1 patient with an idiopathic autoimmune pancytopenia, and 1 patient with immune thrombocytopenia

67 A full blood count revealed pancytopenia, and a peripheral blood film (PBF) showed a

68 d with congenital abnormalities, progressive pancytopenia, and a predisposition to leukemia and solid

69 with the principal diagnosis of hemorrhage/ pancytopenia, and a secondary diagnosis of metastatic he

70 d of mice die due to complications of severe pancytopenia, and about two thirds progress to a fatal a

71 e characterized by congenital abnormalities, pancytopenia, and an increased incidence of cancer.

72 icant lymphadenopathy, fever, liver failure, pancytopenia, and erythrophagocytosis indicative of a he

73 oma presenting with fever of unknown origin, pancytopenia, and exposure to chicken manure.

74 notype had growth and morphological defects, pancytopenia, and impaired erythropoiesis.

75 ee patients experienced prolonged and severe pancytopenia, and in 2 of these patients, efforts to abl

76 locytic ehrlichiosis (HGE) results in fever, pancytopenia, and mild liver injury.

77 MDS, including multi-lineage myelodysplasia, pancytopenia, and occasional progression to overt leukem

78 , hepatotoxicity, interstitial lung disease, pancytopenia, and sepsis [n=1 each]), and two (1%) in th

79 mmatory diseases and characterized by fever, pancytopenia, and systemic inflammation.

80 absence of lymphodepletion died from severe pancytopenia, and this effect was recapitulated by regul

81 [15%] of 62) and decreased neutrophil count, pancytopenia, and thrombocytopenia (two [3%] each).

82 icro Ci) produced no cures, induced profound pancytopenia, and was lethal to all mice.

83 Ataxia-pancytopenia (AP) syndrome is characterized by cerebella

84 infusion was well tolerated, with fever and pancytopenia as the most common adverse events.

85 iglyceridemia associated with rapamycin, and pancytopenia associated with MTX), and 4 were SSc-relate

86 Patients may present with lymphopenia or pancytopenia at diagnosis.

87 Bovine neonatal pancytopenia (BNP; previously known as idiopathic haemor

88 Loss of Chd8 leads to severe anemia, pancytopenia, bone marrow failure, and engraftment failu

89 adult hematopoietic system results in severe pancytopenia but striking accumulation of HSCs and early

90 y immune-mediated bone marrow hypoplasia and pancytopenia, can be treated effectively with immunosupp

91 erations, the TIN2(+/DC) mice developed mild pancytopenia, consistent with hematopoietic dysfunction

92 panied with IBD-like disease with persistent pancytopenia despite moderate-dose G-CSF treatment.

93 We recently identified 3 patients in whom pancytopenia developed almost 50 years after high-level

94 rituximab, and 1 patient with an autoimmune pancytopenia developed PML after treatment with corticos

95 tient became febrile, and leukocytopenia and pancytopenia developed.

96 loblastic anemia, a disease characterized by pancytopenia due to the excessive apoptosis of hematopoi

97 munoconjugates are associated with transient pancytopenia during the first 3 months after treatment.

98 lastic syndrome (MDS) model characterized by pancytopenia, dysmegakaryopoiesis, dyserythropoiesis, an

99 Pancytopenia from marrow-directed GVHD is the primary dr

100 Patients with pancytopenia had sustained high levels of interleukin-18

101 HLS, including fever, multiple organomegaly, pancytopenia, hemophagocytosis, hyperfibrinogenemia with

102 a patient who experienced bleeding episodes, pancytopenia, hepatosplenomegaly, and recurrent pneumoni

103 -deficient mice develop fever, splenomegaly, pancytopenia, hypertriglyceridemia, hypofibrinogenemia,

104 We assessed two families with onset of pancytopenia in adults and detected two novel point muta

105 s may have implications in the management of pancytopenia in AIDS.

106 e, BM hypocellularity, ablation of HSCs, and pancytopenia in control mice, whereas irradiated, EPC-tr

107 e moribund due to hematopoietic failure with pancytopenia in the blood and bone marrow 2 to 6 weeks a

108 irradiated Hoxa-9-/- mice develop persistent pancytopenia, indicating unusual sensitivity to ionizing

109 site of vascular injury in mice with severe pancytopenia induced by total body irradiation.

110 matopoietic recovery and protected mice from pancytopenia-induced death.

111 Pancytopenia is a major cause of morbidity in acute myel

112 egenerative bone marrow failure resulting in pancytopenia is another common problem in advanced stage

113 Pancytopenia is not an uncommon side effect of low-dose

114 opriate management of patients with moderate pancytopenia is unclear.

115 contrast to individuals with LIG4 mutations, pancytopenia leading to bone marrow failure has not been

116 d histological lesions of TA-GVHD, including pancytopenia, marked splenomegaly, wasting, engraftment

117 d by associated physical anomalies and early pancytopenia, may be present in otherwise phenotypically

118 G-CSF) in patients with glycogenosis-related pancytopenia might ameliorate the IBD-like disease throu

119 a hematopoietic stem cell leading to severe pancytopenia, multilineage differentiation impairment, a

120 Both patients presented with severe pancytopenia, multiple opportunistic infections, and fea

121 [(177)Lu]Lu-PSMA-617 plus standard of care (pancytopenia [n=2], bone marrow failure [n=1], subdural

122 3 and G4 events included anemia, leukopenia, pancytopenia, nausea, hyperbilirubinemia, hypophosphatem

123 ive microenvironment that contributes to the pancytopenia observed at diagnosis.

124 GVHD and pancytopenia occur commonly; GVHD is highly correlated w

125 ive trials, yielding an overall incidence of pancytopenia of 1.4% (7 of 511).

126 IST produced significant improvement in the pancytopenia of a substantial proportion of patients wit

127 how that cerebral folate levels, anemia, and pancytopenia of DHFR deficiency can be corrected by trea

128 plus carboplatin-paclitaxel group, only one (pancytopenia) of which was treatment related.

129 he most common grade 3-4 adverse events were pancytopenia (one patient at level 2, one at level 3, an

130 Mortality in the disease results from pancytopenia or transformation to acute myeloid leukemia

131 , and a reduction in almost all blood cells (pancytopenia), or as cutaneous leishmaniasis, characteri

132 icion of GvHD (skin rash, diarrhea, pyrexia, pancytopenia, or anemia, without an obvious alternative

133 ides within neutrophils and can cause fever, pancytopenia, or death.

134 ting persistent fever, hemolytic anemia, and pancytopenia over a 10-month period.

135 rious types of sporadic tumors or idiopathic pancytopenia, peripheral-blood samples from 109 patients

136 induced hematopoietic syndrome and show that pancytopenia persists despite MSC therapy.

137 row hypoplasia, ameliorated peripheral blood pancytopenia, preserved hematopoietic progenitors, and p

138 control group (anaemia, febrile neutropenia, pancytopenia, pulmonary sepsis, respiratory failure, and

139 A total of 70 patients with pancytopenia related to MTX therapy were identified (68

140 bitors and examines the clinical features of pancytopenia related to these drugs.

141 whereas others present with life-threatening pancytopenia representing a medical emergency.

142 od cell count is often incomplete, recurrent pancytopenia requires retreatment, and some patients dev

143 characterized by megaloblastic anemia and/or pancytopenia, severe cerebral folate deficiency, and cer

144 gous control animals receiving MMC exhibited pancytopenia shortly before death.

145 an inborn error of immunity characterized by pancytopenia, skin manifestations, and increased suscept

146 ociated with chromosomal breakage as well as pancytopenia, skin pigmentation, renal hypoplasia, cardi

147 auses a nonlethal phenotype characterized by pancytopenia, splenomegaly, and the accumulation of mono

148 and the genome of an individual with ataxia-pancytopenia syndrome and severe immune dysregulation.

149 nduce the severe marrow hypoplasia and fatal pancytopenia that is produced by injection of similar nu

150 eutropenia (seven [6%]), pyrexia (six [5%]), pancytopenia (three [3%]), and pneumonia (three [3%]).

151 rized by hematopoietic stem cell failure and pancytopenia, to improve platelet counts and stem cell f

152 Relapse was common, but severe pancytopenia usually did not recur.

153 minimal cumulative MTX dose leading to fatal pancytopenia was 10 mg, observed in one of our patients.

154 from reversion in a hematopoietic stem cell, pancytopenia was progressive.

155 Mitomycin C (MMC) dosing, known to induce pancytopenia, was used to challenge the transplanted ani

156 athy and splenomegaly; fever, hepatitis, and pancytopenia were common.

157 predisposing factors for the development of pancytopenia were described.

158 ned risk factors associated with MTX-related pancytopenia were identified.

159 ic cells using Tal1-Cre-ERT also resulted in pancytopenia with decreased HSC numbers.

160 The patient exhibited pancytopenia with decreased neutrophils and T, B, and na

161 l truncated AML1 mutant (S291fsX300) induced pancytopenia with erythroid dysplasia in transplanted mi

162 aplastic anemia, and ERCC6L2 patients, mild pancytopenia with myelodysplasia.

163 Laboratory evaluation revealed pancytopenia with peripheral blasts, and acute myeloid l

164 Affected animals developed fatal pancytopenia within 2 to 3 weeks, accompanied by BM olig

165 lly developed fever, skin rash, diarrhea, or pancytopenia within 2 to 6 weeks after their transplant.

166 Both monkeys recovered from pancytopenia within 4 weeks of whole body irradiation.